Monoclonal antibody-mediated stabilisation and activation of TREM2 on the cell surface reduces AD-related pathology in a mouse model and reduces levels of the homeostatic marker P2Y12 receptor (P2RY12), suggesting that driving microglia toward a disease-associated state might provide a protective function (Schlepckow et al., 2020). This evidence concerns the gene TREM2 and Alzheimer disease.